Please turn JavaScript on
READ
PUBLISH
My newsFind FeedsDelivery settingsPlansMy earnings
HelpBlog
Login
Find more feeds

Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals.

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  4 / week

Message History

GLP‑1s for Adolescents With Type 2 Diabetes and Obesity: A New Era, New Responsibilities

As GLP‑1 therapies expand into pediatric care, a growing number of providers are asking how to best implement them in adolescents diagnosed with both type 2 diabetes and obesity. The conversation around GLP‑1 therapy for adolescents with type 2 diabetes is evolving quickly. With promising clinical results, these therapies bring exciting new potential—but also introduce respon...


Read full story
Inside the GLP‑1/GIP Pipeline: What the Next Wave of Co‑Agonists Could Mean for Care

The GLP‑1 GIP co‑agonist pipeline is ushering in a new era of metabolic therapy that could reshape the way clinicians approach type 2 diabetes and obesity management. As drug developers push beyond single-pathway therapies like GLP‑1 receptor agonists, new combinations—such as GLP‑1/GIP dual agonists and triple agonists—are showing potential to deliver greate...


Read full story
AI Decision Support for CGM and Insulin: How to Use It Without Losing Clinical Judgment

AI decision support in diabetes care is reshaping how clinicians manage continuous glucose monitoring (CGM) and insulin dosing. These tools deliver quick data-driven recommendations, raising key questions: How do we preserve clinical judgment? Where does AI end and provider expertise begin? This article explains how to safely evaluate and use AI tools, set cl...


Read full story
GLP‑1s and Appetite Control: Making Sense of "Food Noise” in the Exam Room

Many patients on GLP‑1 therapy describe their cravings as quieter, their urges to snack reduced, and their minds less consumed by food. This shift, often described as a reduction in “food noise,” reflects significant physiological changes triggered by GLP‑1 medications. As more clinicians prescribe these therapies, it’s vital to understand how GLP‑1s control appetite and crav...


Read full story
Using GLP‑1s in HFpEF and Diabetes: Bringing New Evidence to Breathless Patients

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1...


Read full story